Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Trial Profile

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Methylprednisolone (Primary) ; Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top